School of Medicine
Showing 1-100 of 168 Results
-
Ronjon Nag, PhD
Adjunct Professor, Genetics
BioRonjon Nag is an inventor, teacher and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine, becoming a Stanford Distinguished Careers Institute Fellow in 2016. He teaches AI, Genes, Ethics, Longevity Science and Venture Capital. He is a founder and advisor/board member of multiple start-ups and President of the R42 Group, a venture capital firm which invests in, and creates, AI and Longevity companies. As an AI pioneer of smartphones and app stores, his companies have been sold to Apple, BlackBerry, and Motorola. More recently he has worked on the intersection of AI and Biology. He has been awarded the IET Mountbatten Medal by the Institution of Engineering and Technology, the 2021 IEEE-SCV Outstanding Engineer Award, the $1m Verizon Powerful Answers Award, the 2023 COGX AI Lifetime Achievement Award, the 2023 MIT Great Dome Award, and was the 2024 Inductee in the Silicon Valley Engineering Hall of Fame. Professor Nag has a Ph.D from Cambridge, an M.S from Massachusetts Institute of Technology and a B.Sc. from Birmingham in the UK. He has numerous interests in the intersection of AI and Healthcare including being CEO of Agemica.ai working on creating a vaccine for aging.
He has many firsts including:
Firsts:
• First laptop with speech recognition built-in (with Apricot, 1984)
• First selling cursive handwriting recognition (with Lexicus, 1991)
• First speech recognition phones (with Lexicus/Motorola, 1996)
• First large-vocabulary Chinese speech recognition (with Lexicus/Motorola, 1996)
• First Chinese predictive text system on a phone (Lexicus/Motorola, 1997)
• First predictive text systems in 40 languages on Motorola phones, (Lexicus/Motorola, 1997)
• First touch screen mobile phone with handwriting recognition (Lexicus/Motorola, 1999)
• First combined mobile search engine and directory (with Cellmania, 2000)
• First private label downloadable operator billable apps store (Cellmania, 2000)
• First BlackBerry Operator Billing apps store (Cellmania,2010)
• First Neural Network Artificial Intelligence System in the Cloud (Ersatz Labs, 2014)
• First Throwable 360 Ball Camera (Bounce Imaging, 2015)
• First Android powered smart light switch (Brightswitch 2017)
• First blood pressure watch with temperature and pulse oximetry add-ons for Back to Work Covid Kit (GTCardio 2019)
• First no code AI life sciences app store (Superbio.ai 2022)
• First proposal for an aging vaccine (Agemica 2023) -
Ramesh Nair
Director of Bioinformatics, SCGPM, Genetics
Current Role at StanfordDirector, Bioinformatics
Stanford Center for Genomics and Personalized Medicine (SCGPM)
Bioinformatics-as-a-Service (BaaS)
Genetics Bioinformatics Service Center (GBSC)
Diabetes Genomics Analysis Core (DGAC)
Stanford University School of Medicine -
Michitaka Nakano
Basic Life Research Scientist, Medicine - Med/Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
-
Yusuke Nakauchi, MD, PhD
Basic Life Research Scientist, Stem Cell Bio Regenerative Med Institute
BioMy research projects aim to investigate the biology of human leukemia. I believe my research will contribute to clarify the disease pathogenesis of leukemia and help identify the critical cells to target to both prevent the development of de novo leukemia and halt relapse.
-
Anjali Nambiar, BS
Social Science Research Professional 1, Stanford-Surgery Policy Improvement Research and Education Center
BioAnjali Nambiar is a Research Coordinator at the Surgery Policy Improvement Research and Education (S-SPIRE) Center. She holds a degree in Biological Sciences and has experience supporting clinical research across various specialties, as well as in implementing new programs at community-based clinics and organizations.
-
Arutselvan Natarajan
Senior Research Scientist - Basic Life, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordSenior Scientist
-
Michael Nedelman
Adjunct Lecturer, Medicine - Primary Care and Population Health
BioDr. Michael Nedelman leads the Stanford Health Equity Media Fellowship. He previously covered health and medicine as a journalist for CNN, earning an Emmy nomination for the network's acclaimed reporting on the Covid-19 pandemic. As producer for the inimitable Dr. Sanjay Gupta, he was part of a team known for excellent reporting and storytelling — also winning a Cronkite Award for tackling misinformation during the pandemic. Before CNN, he was a digital producer for the ABC News Medical Unit, worked on public health campaigns at the World Health Organization in New Delhi, and trained at the Stanford Journalism Program as part of the university's Global Health Media Fellowship. He received his MD from Stanford and did his undergraduate work in film at Yale.
-
Margaret Jane Neff
Clinical Associate Professor (Affiliated), Medicine - Med/Pulmonary, Allergy & Critical Care Medicine
Medical Director--Vapahcs Medical Surgical Icu, Medicine - Med/Pulmonary, Allergy & Critical Care MedicineBioMy training is in Pulmonary & Critical Care Medicine, and I've been blessed to be part of the care of many patients and their families. My clinical research interests have been in the field of critical care medicine and ARDS, a type of acute respiratory failure seen commonly in patients with severe injuries or illnesses. I also have a particular interest in evaluating and improving processes for care. Issues like standardizing processes to improve reliability, improving safety of handoffs, and exploring ways to teach "roundsmanship" (the process of discussing patients' care with a group of providers) are current interests of mine.
The future of medical care depends on training the next generation of providers, and I'm thankful to be part of training this next generation. Teaching at the bedside or in formal classroom settings gives me great joy and satisfaction. I'm delighted to work with a great, multidisciplinary team of physicians, nurse practitioners, nurses, respiratory therapists, and pharmacists. I add to that team our patients and families, for it truly takes a team to provide care that is both excellent and compassionate. -
Hesam N. Motlagh
Adjunct Professor, Structural Biology
BioHesam is passionate about translating basic science discoveries into products that have a significant impact on society. He is Chief of Staff at Khosla Ventures where he works with Vinod Khosla on strategic projects for the firm and advises portfolio companies on fundraising, product, business development, marketing, and general strategy.
Currently, Hesam is an Adjunct Professor in the Department of Structural Biology at Stanford Medicine and a Fellow in The Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise where he is editor of the Studies in Applied Finance. Previously, he worked on financial and corporate strategy at Seer Biosciences and was a Pear Fellow at Pear VC. Before Seer, he was a quant at an investment management firm after being a molecular and computational biophysicist for almost a decade.
Hesam has many peer-reviewed publications including a review article that was highlighted on the cover of Nature. He completed his MBA at Stanford Graduate School of Business, obtained his PhD from the Program in Molecular Biophysics at The Johns Hopkins University under the supervision of Vincent Hilser, and obtained his undergraduate degrees from Miami University in Oxford, Ohio. -
Gernot Neumayer
Senior Research Scientist, Stem Cell Bio Regenerative Med Institute
Current Role at StanfordSenior Scientist
